Acrivon Therapeutics, Inc. Common Stock (ACRV) vs Hyperfine, Inc. (HYPR)

A side-by-side comparison of Acrivon Therapeutics, Inc. Common Stock and Hyperfine, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Acrivon Therapeutics, Inc. Common Stock logo
ACRV
Acrivon Therapeutics, Inc. Common Stock
$83M
$1.94HealthcareDelayed quote: Oct 6, 2026, 12:45 PM EDT
Hyperfine, Inc. logo
HYPR
Hyperfine, Inc.
$75M
$0.89HealthcareDelayed quote: Oct 6, 2026, 12:38 PM EDT

Total return — ACRV vs HYPR

growth of $100 · dividends reinvested · last 4y
ACRV -88.1% (-41.3%/yr)HYPR -5.1% (-1.3%/yr)HYPR compounded faster over this window
Log scale — wide-divergence pair
1101001kStart $1002023202420252026$12$95
ACRV HYPR

ACRV vs HYPR: by the numbers

  • •ACRV is the larger company ($83M vs $75M market cap).
  • •Both run net losses; ACRV's is the smaller (0.00% vs -210.75% net margin).

Metrics side by side

Valuation

MetricACRVHYPR
P/S ratioN/A4.51
P/B ratio0.962.03

Profitability

MetricACRVHYPR
Gross margin0.00%51.41%
Operating margin0.00%-273.43%
Net margin0.00%-210.75%
ROE-85.65%-94.81%
ROIC-88.28%-62.98%

Growth (annualized)

MetricACRVHYPR
Revenue CAGR (5Y)N/A77.73%
Total return CAGR (5Y)N/A-38.34%

Go deeper

Full ACRV analysisFull HYPR analysisInteractive comparison tool

Dig into the metrics

Acrivon Therapeutics, Inc. Common Stock ROEHyperfine ROEAcrivon Therapeutics, Inc. Common Stock operating marginHyperfine operating marginAcrivon Therapeutics, Inc. Common Stock revenue growthHyperfine revenue growthAcrivon Therapeutics, Inc. Common Stock free cash flowHyperfine free cash flow

Acrivon Therapeutics, Inc. Common Stock & Hyperfine appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.